International Journal of Medicine and Data

Among the common malignant tumors in women, breast cancer is one of the relatively common types, most patients find the disease by touching breast nodules or physical examination, and the malignant tumor is advanced when the corresponding clinical manifestations or signs appear. One of the main treatment measures for breast cancer at this stage includes neoadjuvant chemotherapy. Neoadjuvant chemotherapy is the first systemic treatment that a patient receives before undergoing local therapy such as surgery or radiation therapy. After long-term practice, it has been found that patients receiving neoadjuvant chemotherapy have lower pathological stages in breast cancer patients, which has positive significance for improving the surgical resection rate, breast conserving success rate, inhibition of metastasis, and assessing the sensitivity of related chemotherapy drugs. In recent years, with the deepening of research, it has been found that cell proliferation nuclear antigen (Ki-67) can effectively reflect the activity of cell proliferation of patients, and domestic studies have pointed out that individualized precision chemotherapy regimen can effectively improve the patients condition and prolong the survival of the patient, but there is still no clear conclusion, this article will explore and analyze the effect of epirubicin combined with docetaxel neoadjuvant chemotherapy on cancer tissue Ki-67.

epirubixin; Docitaxel; Neoadjuvant chemotherapy; Breast cancer; Ki-67